Maxim Maintains Buy On Aeterna Zentaris Ahead Of Zoptarelin-Dox Data
In a research report sent to investors today, Maxim Group analyst Jason Kolbert maintained a Buy rating on Aeterna Zentaris (NASDAQ:AEZS) with a $2.00 price target, which implies an upside of 251% from current levels.
Kolbert said, “Zoptarelin-Dox data (interim analysis) in 2H15 represents a key event for the company. We believe that the incremental improvements to this standard of care agent should make it a low risk, high probability of positive outcome event.”
According to TipRanks, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Jason Kolbert has a total average return of 1.1% and a 38.0% success rate. Kolbert has -30.4% average return when recommending AEZS, and is ranked #1653 out of 3426 analysts.